Target intelligence / Profile preview

WAC antisense RNA 1 (WAC-AS1)

Target
WAC-AS1
Molecular classification
Long non-coding RNA (lncRNA), Natural antisense transcript (NAT)
01

Overview

WAC antisense RNA 1 (WAC-AS1) is a long non-coding RNA (lncRNA) transcribed antisense to the WAC gene at the chromosomal locus 10p12.1. It is part of a class of RNA molecules typically longer than 200 nucleotides that do not encode proteins but regulate gene expression and cellular functions. WAC-AS1 participates in multiple biological processes, especially in cancer, where it is implicated in regulation of tumor proliferation, progression, cell cycle, and glycolysis. It has context-dependent effects: acting as a protective factor in certain cancers (e.g., glioma) and a risk factor in others (e.g., hepatocellular carcinoma). WAC-AS1 also modulates immune cell infiltration and the tumor microenvironment, and plays a role in Hepatitis B virus replication by regulating autophagy pathways. While considered a biomarker for prognosis and disease characterization in some cancers, there is no evidence it is currently a direct target of any approved therapeutic agents

Other names
WAC Antisense RNA 1 (Head To Head)NONHSAG005482.2HSALNG0076905
02

Mechanism of action

Not directly targeted by drugs; acts as a functional regulator via competing endogenous RNA (ceRNA), influencing microRNAs (e.g., miR-320d, miR-192-5p) and modulating downstream gene expression in cancer and infection

03

Biological functions

Regulation of tumor proliferation and progressionRegulation of glycolysisRegulation of cell cycleModulation of tumor microenvironment and immune infiltrationRegulation of autophagy in viral infection
04

Disease associations

Cancer (including hepatocellular carcinoma, glioma, ovarian cancer, breast cancer, gastric cancer, and others)Infection (Hepatitis B virus replication)
05

Biomarkers

Expression levels of WAC-AS1 as a prognostic marker for survival in glioma and ovarian cancerPotential biomarker for liver cancer progressionMarker of immune infiltration and tumor microenvironment in pan-cancer analysis

Beyond the preview

Go deeper on WAC antisense RNA 1 (WAC-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on WAC antisense RNA 1 (WAC-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call